• Company has completed three profitable strategic acquisitions during 2017
• Revenue has increased 378-fold since first quarter 2017
• Ideally positioned to continue acquisition strategy and further grow revenues

In singling out success stories within the cannabis industry, SinglePoint, Inc. (OTC: SING) is a company that has definitely earned its place among the members of the marijuana market’s “Who’s Who.”

SinglePoint has been pursuing a diversified acquisition strategy within the cannabis industry this year with great success—something discussed in detail in a recently published article (http://dtn.fm/8wszX).

SinglePoint has evolved within a short time from having its core focus on advanced payment technologies and full-service mobile technologies, leveraging the its SingleSeed subsidiary to becoming a fully functioning holding company engaged in the acquisition of small- to mid-sized companies. Thus, SinglePoint has strategically established profitable footholds in the burgeoning cannabis market—all without touching the marijuana plant.

In late January 2017, SinglePoint announced the signing of a letter of intent to acquire an interest in Jacksam Corp., dba Convectium, closing the first round of funding for the acquisition in March. This acquisition marked the first in a successive—and ongoing—line of strategic investments intended to diversify SinglePoint’s revenue streams within the multibillion-dollar marijuana industry.

Convectium is a provider of equipment, branding and packaging solutions to the marijuana industry and the developer of the very first cartridge and vape pen oil-filling machines for wholesale distribution to cannabis dispensaries. The company’s 710Shark and 710Seal machines, sold through EquipCanna.com, are able to fill and package more than 100 cartridges or disposable vape pens in a mere 30 seconds. Additionally, Convectium operates B2C consumer brands that include BlackoutX and HazeSticks.

In May, SinglePoint acquired 90 percent of Discount Indoor Garden Supply (DIGS) in a stock and cash transaction, which immediately positioned SinglePoint as a leader in online products, retail stores, cannabis consulting and equipment in California. DIGS offers a broad array of growing equipment and accessories for individual and commercial plant cultivators, including growing supplies, hydroponic garden solutions, grow rooms and accessories, all-in-one units enabling private plant growth within the home, and more.

Teaming up with First Bitcoin Capital Corp. (OTC: BITCF), SinglePoint has additionally been engaged in developing a blockchain payments solution to enable cannabis enterprises to process debit and credit card payments using bitcoin—independent of federal sanction, which, at present, marijuana businesses in the United States do not have and, therefore, lack traditional banking options and have been forced to conduct transactions in cash.

Related to the development of its cryptocurrency payments solution, in August SinglePoint announced its purchase of $Weed from First Bitcoin Capital, which is a marijuana-specific cryptocurrency that recently had an initial coin offering launch that resulted in an impressive yet illiquid market cap of almost $60 million. $Weed currency is now being integrated into SinglePoint’s bitcoin payments solution.

On September 6, SinglePoint finalized its acquisition of profitable cannabis distribution company Dr. FeelGood, which offers a wide variety of products distributed through both B2B and B2C models.

It has, indeed, been a busy and profitable year for SinglePoint. As a result of its acquisition activity, the company’s revenue has increased 378-fold in contrast with its first quarter 2017 earnings, and SinglePoint is ideally positioned and well-capitalized to further its acquisition strategy and continue increasing its revenues going forward.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board

• SWRM has been restructured for growth, projects $6-7 million revenues by 2018
• Total global mobile gaming expected to grow to $58.1 billion by 2018, estimated to show 15% YOY growth in 2017
• SuperDataResearch Report: In global dollars, mobile gaming is largest digital platform of interactive media revenue

AppSwarm, Inc. (OTC: SWRM) split into two divisions when it acquired MediaPlay in mid-August 2017, and the company is now positioned to take a bigger role internationally in the large and fast-growing global mobile gaming market.

Ron Brewer, CEO and director of the company, calls SWRM a high technology acceleration firm in the multi-platform games industry. It remains as one company after the restructuring, but it has two interactive divisions. The first is MediaPlay, a games publisher focused internationally on larger projects, such as supplying services to TV channels. The second is Incubation and Acquisition Development (IAD), which is charged with acquisitions, pursuing gaming opportunities and providing e-commerce business solutions to enhance SWRM’s organic and new growth.

Mobile gaming represents a $50.3 billion global market in 2017, and it is projected to reach $58.1 billion in 2018, according to the SuperDataResearch report “Trends and Insights On Games and Interactive Media 2017” (http://dtn.fm/Qa855). The report also found that 46% of the gamers in the U.S. are women, and the number of consumers who watch video game content online is roughly 665 million in 2017. The research firm estimates that more people will watch video gaming content in 2017 than those who watch HBO, Netflix, ESPN, and Hulu combined.

Brewer said in an interview (http://dtn.fm/LfM8z) that his management team projects sales of $6-7 million by FY2018. The company recently entered into a joint venture with Estorerunner, a nationally franchised “on-demand” delivery service for local grocery stores and pharmacies.

AppSwarm also recently announced that it is developing a proprietary “last-mile” delivery app platform “for management and implementation needs that create highly enhanced efficiencies” (http://dtn.fm/Y7Hyn).

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• CIIX’s goal is 100% growth, cost cuts and profitability in FY2018 after recording 76% YOY operating sales jump in FY2017
• Valuation of CIIX “could explode with this huge potential market in China of 1.4 billion people,” according to investor relations director in SmallCapVoice interview
• Consilium Global Research projects CIIX sales will reach $14.8 million by FY2020

ChineseInvestors.com, Inc. (OTCQB: CIIX) is growing in numerous directions due to its diverse strategy of marketing, communications and product development both within China and to the global Chinese-speaking community. After recording YOY operating sales gains of 130% in investor relations and 57% in subscription revenue in FY2017, CEO Warren Wang said that the company’s goal is 100% more growth in FY2018 while cutting costs and achieving profitability. Overall, the company showed 76% YOY operating sales growth in FY2017. Diversity is the key to this skyrocketing growth (http://dtn.fm/e57MB).

Through its subsidiary, CBD Biotechnology Co. Ltd., CIIX is marketing, to the 1.4 billion people of China, its CBD-infused skin care line through multiple-channels, including retail, social media and direct marketing, Alan Klitenic, director of investor relations for CIIX, told SmallCapVoice.com in an interview (http://dtn.fm/DSL8n).

CIIX has a goal of becoming the primary Chinese publicly traded company in the medical cannabis industry. Its focus is on distributing legalized cannabidiol (CBD) to the worldwide Chinese-speaking community. Consilium Global Research projects that CIIX sales will reach $14.8 million by FY2020 (http://dtn.fm/2rzPY). The Hemp Business Journal estimates that the CBD market will reach $2.1 billion in consumer sales by FY2020, showing a compound annual growth rate (CAGR) of 80%, per Consilium Global Research.

Klitenic added that CIIX’s two divisions exhibited double- and triple-digit growth in FY2017. As it markets its line of hemp oil-infused skin care products, he said, the firm will target a large audience in China and the U.S. “We will also be selling through ecommerce on eBay and Amazon,” he said. “Our goal is to maximize revenues and shareholder value.”

He explained that by marketing the regulatory agency-approved CBD-infused skin care line in China, “Our valuation could explode with this huge potential market.” Klitenic said that the company is ready to make sales in China and spend dollars to be promotional and build its brand. Cannabis is known to have anti-inflammatory and antioxidant properties. The products have fatty acids in their hemp seed oil that improve skin complexion and maintain the skin’s moisture, according to company data.

Klitenic also noted that, this month, CIIX is planning to start broadcasting from the NYSE to its Chinese-speaking audience, offering information and video news about cryptocurrencies. “We are only an educational and news provider,” he said, aiming to answer the many questions it receives. “We recently acquired the domain name, newcoin168.com, to begin offering this video news service.”

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Seeks patent on new therapy for drug that employs concentrations of THC
• Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss
• IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product

India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://dtn.fm/Rcl69). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron damage.

This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.

IGC is a first-mover in the cannabis-based combination therapy space. The Bethesda, Maryland-based company has already filed for six patents in the markets of epilepsy, eating disorders and pain. It is also working on additional filings for indications including depression, Alzheimer’s disease, post-traumatic stress disorder and Parkinson’s disease.

“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” IGC CEO Ram Mukunda stated in a news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50% and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.”

It is believed that a primary cause of Alzheimer’s disease is the buildup of senile plaque, or Aβ plaque, in the cerebral cortex and hippocampus. As the disease progresses, Aβ oligomers directly cause synaptic dysfunction and the death of neurons, leading to memory loss.

“In vitro, our product demonstrates these critical factors and we are pursuing a patent filing that protects this therapy,” Mukunda added.

IGC has a two-step plan. First, it will position IGC-AD1 both as a treatment and a preventative therapy for Alzheimer’s. Second, IGC plans to commercialize a supplement version of the drug to be sold as a medical dispensary product.

Alzheimer’s affects more than 5.3 million Americans, and more than 65% of the patients suffering from the disease are women. It is known as America’s most expensive disease, costing the economy an estimated $236 billion. Over the next 20 years, the number of people with the disease is expected to double. Alzheimer’s begins 20-25 years prior to clear symptoms. To date, no effective cure has been found.

For more information, visit the company’s website at www.IGCInc.us

• Price of zinc recently rose to $3,369 per metric ton, reaching highest point in more than a decade
• Estimated recovery rate of 95% for zinc seen at the Blue Moon site a key catalyst to its future development
• CEO Patrick McGrath calls the site “one of the best near-term development assets” in zinc mining

For Blue Moon Zinc Corp. (TSX.V: MOON) (OTC: BMOOF), the best may be yet to come. As zinc continues to rise in value, hovering near $3,369 per metric ton at time of writing (http://dtn.fm/N6uUg), the company is focused on its Blue Moon Project, located in Mariposa County, California. Zinc is used widely, largely in the manufacture of batteries and auto parts, but it has the future potential to be used in zinc-based batteries for electric cars and other energy storage applications.

Patrick McGrath, CEO, was originally just a shareholder of the junior zinc development company, but he said in a recent interview (http://dtn.fm/z8lKS) that he saw in Blue Moon, “one of the best near-term development assets” in zinc mining. He added that prior mid-tier mining companies had already done “most of the heavy lifting for us.” The project remained dormant after early work on the site for a number of reasons, most notably low zinc prices, but BMOOF estimates that there are some 377 million pounds of zinc indicated in the project and 395 million pounds inferred at the site, citing a recently completed mineral resource estimate (http://dtn.fm/IycK8).

Another reason other mining companies were reluctant to become involved in the site was California’s reputation for being “tough” in granting mining permits, but McGrath said that obtaining project permits within that state is no tougher than elsewhere, effectively “leveling the playing field.” A high estimated recovery rate of 95% for zinc at Blue Moon’s site is key to the company’s future development, McGrath said. The Blue Moon deposit is located on 525 acres in the foothills of the Sierra Nevada Mountains.

Although the market cap for the company is just $4.7 million, McGrath described BMOOF as being a great long-term investment for several reasons. One is its robust short-term “catalyst” in the next three months: its projected 1Q18 Preliminary Economic Assessment (PEA). The company said the PEA for the site would show its potential for economic development. The PEA, according to McGrath, should indicate Blue Moon as a viable stand-alone project. Next, the Blue Moon deposit is a volcanic massive sulphide (VMS) deposit, which are often found in ‘pods,’ indicating that more zinc deposits may be nearby.

McGrath said he sees a “high likelihood” that the Blue Moon project will offer an upside prospect for investors seeking exposure to zinc.

For more information, visit the company’s website at www.BlueMoonMining.com

Let us hear your thoughts: Blue Moon Zinc Corp. Message Board

• Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream
• It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products
• Patents have been awarded in the U.S. and Australia and are pending in 44 countries

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology is already being applied to the use of non-psychoactive cannabinoids. This innovation has yielded a high absorption hemp oil formula that is a source of omega and fatty acids.

The health benefits of the technology and the products it has enabled are many. Lexaria has developed a product that can reduce anxiety and stress, increase mental focus and boost physiological performance and recovery. It can reduce pain and inflammation as well, while acting as a vasodilator to improve circulation.

Improved bioabsorption and lowering the cost of edibles are not the only perks of LXRP’s technology. The boost to the product market, and to investors, is already being felt. Avoiding the need for inhalation or co-administering CBD with sugars or sweeteners, the technology accelerates intestinal absorption. This has enabled the development of protein energy bars for sports nutrition and chewable CBD tablets with no sugar. Hemp oil capsules in the TurboCBD™ brand (with American ginseng and Ginkgo biloba) and teas have also been developed.

Lexaria’s technology works by masking the taste of cannabinoids as they’re consumed. It also protects the bioactive ingredients as they pass through the stomach and increases bioabsorption in the intestines by 5–10X. This rate is about equal to that of inhalation, offering a viable alternative to smoking. Onset times are also reduced. Effects may be felt with 15–20 minutes, in contrast to up to two hours via other means.

The patent awarded to LXRP for the delivery of all non-psychoactive cannabinoids makes Lexaria the first company in the world to achieve this accomplishment. Awarded in the U.S. and Australia, it is now pending in 44 other countries while supporting research and development on cannabinoids across the industry. The company has filed 19 patent applications in the U.S. and internationally. It also expects additional patent acceptances and issuances in 2017 and over the coming years.

In fact, Lexaria has out-licensed the technology as part of its royalty business model, allowing third-party partners and distributors to profit and support their own developments. The numerous deals already signed include those in various state markets, including California, Colorado and Nevada, and a distribution agreement for CBD chewables in Japan and South Korea. Lexaria’s first royalty agreement was with a fast-growing startup, but current negotiations are with larger, more established enterprises. Lexaria is expanding its global reach and expects to continue seeing growth in business deals in broader industry sectors with more well-known consumer brands.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Global alternative fuel and hybrid vehicle market projected to reach $819 billion by 2024
• Demand for alternative fuel vehicles is increasing worldwide
• Clean, cost-efficient commercial trucks are a booming market as more companies go green

Greenkraft, Inc. (OTCQB: GKIT), a California-based manufacturer of alternative fuel automotive products including engines and commercial trucks, offers eco-friendly trucks that are reliable, cost-effective and versatile. This rapidly growing sector of the automotive industry is demanding cleaner, more fuel-efficient models utilizing alternative fuels. Greenkraft’s new line of larger trucks, powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7, provide an option for businesses seeking to have less of an impact on the environment while saving money.

The global alternative fuel and hybrid vehicle market, valued at $318 billion in 2016, is expected to reach $819 billion by 2024, recording a compound annual growth rate of 12.8 percent, according to a September 2017 Esticast Research & Consulting report (http://dtn.fm/9pNcT). Advancements in alternative fuel technologies, increasing interest in eco-friendly vehicles and an upsurge in government initiatives are expected to help push the industry forward.

One major player in the trucking industry, UPS, announced in June that it would add more alternative fuel and advanced technology vehicles to its fleet while increasing its reliance on renewable energy sources. The company set a goal that, by 2020, one in every four vehicles purchased annually for its ground fleet would be an alternative fuel or advanced technology vehicle (http://dtn.fm/KDm7R).

This move toward using more diverse and sustainable energy sources is being embraced by smaller companies and a variety of industries, as well. Earlier this year, Greenkraft successfully debuted an alternative fuel truck at the WWETT Show 2017 held in Indiana. CEO George Gemayel said the truck was well received by members of the septic tank sector of the trucking industry, noting Greenkraft’s entry into the specialized truck market could generate millions more in revenue (http://dtn.fm/G1fwZ).

Each product produced by Greenkraft provides environmentally friendly solutions to the increasingly difficult problems associated with using traditional fuels. While most vehicles across the United States are powered by either gasoline or diesel, Greenkraft manufactures and markets alternative fuel systems to convert these engines to function on natural gas and propane fuels. The company’s fuel-efficient trucks not only save businesses money, but avoid pumping tons of greenhouse gasses into the atmosphere – and that’s a win-win for any industry.

For more information, visit the company’s website at www.GreenkraftInc.com

Let us hear your thoughts: Greenkraft, Inc. Message Board

• Diversified portfolio of 300+ mobile gaming titles with hundreds of millions of players
• Full-Featured Game revenues expected to increase more than 200% in 2017 with launch of new games and other mobile entertainment updates
• Worldwide mobile gaming revenue projected to reach $74.6 billion by 2020 with mobile advertising revenue topping $166 billion by 2018

Tapinator, Inc. (OTCQB: TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company’s portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator’s business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as “New Games We Love.” During the game’s first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator’s strong creative team of developers, strategists and product specialists. The company’s Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator’s diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game’s currency. Tapinator’s portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator’s gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019.

For more information, visit the company’s website at www.Tapinator.com

Let us hear your thoughts: Tapinator, Inc. Message Board

• Forbes predicts medical marijuana sales to reach $13.3 billion by 2020
• Biotech/pharma market could surpass $20 billion by 2020, per estimates from Viridian Capital Advisors
• InMed’s biosynthesis process uses DNA and E. coli to produce cannabinoids that are identical to the 90+ found in nature
• The company’s pipeline drugs, focusing on rare dermatological diseases, glaucoma and topical pain treatments, are advancing toward clinical trials

There may be many companies exploring cannabinoid biosynthesis, but one in particular stands out. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has created a revolutionary process that is poised to impact the cannabinoid market. It’s just one of several companies mentioned in a recent industry article (http://dtn.fm/5OP0a) that are actively engaged in the race to synthesize the 90+ known cannabinoids in their natural forms.

InMed’s process involves using the genetic material of naturally occurring cannabinoids. By introducing their DNA in a controlled laboratory setting, scientists can create compounds that are identical to those found in nature. Each cannabinoid has the same chemical makeup as its natural counterpart. The difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis, and then extracting the individual cannabinoids for medical use, are greatly diminished. Biosynthesis also eliminates the need for fertilizers and pesticides that can be toxic to people and harmful to the environment.

Cultivating cannabis plants also requires a great deal of manpower, not to mention resources such as electricity and water. Biosynthesis not only promises to reduce the time and effort required to extract cannabinoids; it also has the potential to expedite drug development. InMed’s approach in this area was highlighted in a recent article (http://dtn.fm/Um29W) in which its E. coli-based biosynthesis platform and the potential ability to tap into the medial benefits of every cannabinoid are noted. The E. coli-based expression system utilizes an optimized gene construct to maximize production.

The company is exploring the potential in the dermatology field for its INM-750 drug candidate for epidermolysis bullosa. Cannabinoids have shown positive results in pre-clinical testing, addressing the major hallmarks of the disease, including wound healing, pain, itch, inflammation and antimicrobial control. Of particular note are the encouraging results that show INM-750 as having the potential to modulate keratin levels, which, if successful, may modulate the course of the disease itself, a game changer for patients and for the company. InMed is also conducting testing for its ocular treatment, INM-085 for glaucoma, and pain therapy with INM-405. Capable of reducing intra-ocular pressure and protecting nerve cells and tissues in the eye, INM-085 has a proprietary delivery system, a hydro-gel, that has been engineered as a specific delivery vehicle for ocular disease.

However, the company isn’t only being touted for its biosynthesis process and drug development. It has also developed a proprietary bioinformatics system. This computer-based drug/disease targeting tool enables researchers to identify cannabinoids suitable for treating specific conditions based on drug structures, protein-protein interactions, gene regulation, cell signaling and other biological processes. This approach has been validated in advanced pre-clinical models of disease for InMed’s several development programs.

The company’s research focus extends beyond skin, eye and pain treatments. It is also studying the potential effects of cannabinoids on nervous system disorders such as Huntington’s disease. Cannabinoid research is taking place at several institutions in respiratory science, with ongoing studies into possible asthma and chronic obstructive pulmonary disease therapies. Other advances in cannabinoid science include the potential for treating diabetes, obesity and other metabolic conditions. Thus, InMed’s biosynthesis process may play an integral role in advancing drug development both internally and with other entities by making specific compounds readily available for research and commercialization.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

• LTTGF names actor William Shatner as media spokesperson and Kevin Harrington, an original Shark on TV’s Shark Tank, as board member
• Company is an online lottery messenger service designed to disrupt the $70-80 billion U.S. lottery market
• Company goal is to grow to nearly $50 million annually by 2020 on a paid subscriber base of approximately 500,000 as it expands to 22 more states from its California base

LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) provides online services to lottery consumers. By naming celebrity actor William Shatner as its spokesperson and Shark Tank original Kevin Harrington to its board, the company is using celebrity connections/endorsements as a proven strategy to grow, helping to drive its plans to expand into more states and increase its share of the $70-80 billion U.S. lottery market.

LTTGF acts as a lottery messenger service that enables its customers to buy tickets for state lotteries online with credit or debit cards. The company currently operates only in California, which itself has a $6.3 billion lottery market, but it is already planning to expand into 22 more states as it moves to become national.

A new 30-second TV ad with William Shatner (http://dtn.fm/quJK4) illustrates the simplicity of using LottoGopher while disparaging the practice of waiting in line at a store to buy tickets. LTTGF’s goals by 2020 are annual sales of nearly $50 million on a paying subscriber base of approximately 500,000 as it grows into 22 more states from its current base in California (http://dtn.fm/AjeL8). In a recent news release, James Morel, president and CEO of the company, added, “In the past few months we have seen an uptick in subscriptions and we want to continue this momentum.”

A recent article points out how celebrity endorsements are a proven winning strategy utilized by companies to gain awareness, loyalty and, ultimately, market share through higher revenues (http://dtn.fm/C1MBq). Weight Watchers International, Inc. (NYSE: WTW) is associated with Oprah Winfrey, Johnson & Johnson (NYSE: JNJ) and The Coca-Cola Company (NYSE: KO) named actress Jennifer Aniston as the face of their Aveeno and Smartwater brands and Diageo PLC (NYSE: DEO) named Sean “Diddy” Combs as spokesperson and joint venture partner.

Weight Watchers became associated with celebrity Oprah Winfrey in 2015 when she purchased 10% of the company’s shares. In December 2016, Weight Watchers shares skyrocketed 16% when she starred in a new ad campaign for the company. Sean “Diddy” Combs joined British multinational alcoholic beverage company Diageo PLC as its joint-venture partner and spokesperson in 2007, before signing a subsequent deal in 2014. In that time, Diageo’s stock has soared from $91.75 in 2007 to $132.13 today.

LottoGopher hopes to see similar success. Shatner (http://dtn.fm/5Id9E), best known for his role in Star Trek, adds, “Much like Netflix disrupted the movie rental business, and Uber hailing a cab, LottoGopher is disrupting the lottery industry for Americans. Consumers nowadays demand exceptional service, competitive pricing, and the convenience of buying products online.”

LTTGF enables paying subscribers the ability to purchase Powerball, Mega Millions and SuperLotto Plus tickets online for no additional fees. The company permits players to use digital currencies, such as bitcoin. The service offers players not only the physical line-free efficient purchase of tickets, but also lucky numbers and the latest lottery news. Individuals have the option to play alone or join online groups to pool tickets and share the winnings.

In using the paid subscription model to grow its base, LTTGF also offers a free purchase of a lottery ticket to new players so that they can try out the system. Players can purchase a single day, monthly, or yearly pass to the site. Former Shark Harrington told online site Benzinga the service is the “Uber Eats” of lotteries (http://dtn.fm/6Aw04). “LottoGopher will be using TV, radio, digital media, celebrity endorsements … all the resources that are available,” he said.

Together, LTTGF’s successful business model and its move to utilize the proven marketing strategy of celebrity endorsements, represent a one-two punch for the rapidly growing lottery market.

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board